VSTM: Short sellers rebuilding ahead of a catalyst-packed fortnight

Verastem heads into a ten-day window containing both an earnings print and a potential index announcement with short sellers adding aggressively and options traders conspicuously unbothered by either.

The short interest picture is the week's clearest tension. Short interest jumped 19% in a single session on October 26, lifting the total to 22.7% of the free float, a level that qualifies as genuinely high for a small-cap biotech. The weekly gain is 24%, reversing a month-long decline that had pulled shorts down from the 19 million share range seen in late September and early October. The direction-of-travel has flipped sharply. FINRA's most recent fortnightly confirmation puts shorts at 17.2 million shares with a 2.5 days-to-cover, and the ORTEX short score has edged up to 63.2, near the top of its ten-day range. Bears are rebuilding positions into catalysts, not exiting them.

The lending market does not, however, signal a squeeze in the making. Availability has actually loosened over the past week, rising to 350% of short interest. That means roughly three and a half shares are available for every one already borrowed, well above the year's tightest reading of 119%. Cost to borrow is 0.55%, barely above last week's 0.49% and negligible by any measure. A short interest of 22.7% is meaningful, but the borrow market is not under strain, which limits the mechanical squeeze risk that tends to accelerate moves in tightly held names. Options confirm the lack of alarm: the put/call ratio is 0.22, almost exactly in line with its 20-day average of 0.22, and far closer to its 52-week low of 0.03 than its high of 1.65. Calls dominate the open interest, suggesting the options market is still leaning bullish.

The Street is also constructive, and has grown more so over the past two weeks. Multiple firms raised price targets following what appears to have been a data or commercial update in mid-October. RBC Capital lifted its target from $14 to $19. Mizuho raised from $13 to $14. Jefferies moved from $11 to $13. BTIG went from $18 to $24, the highest on the Street, and reiterated Buy again on October 19. All nine analysts tracked carry a buy-equivalent rating. The bull case centres on the approved LGSOC therapy AVMAPKI FAKZYNJA providing a revenue floor while VS-7375 targets the broader KRAS G12D opportunity, with a combined market opportunity cited above $1.3 billion. The bear case is narrower but pointed: RAMP-301 failure or a slow launch trajectory could compress the stock toward net cash, and the indication is small enough that patient enrollment is a genuine execution risk. At $10, the stock trades well below every active target, with even the most cautious Street estimate implying meaningful upside. However, some historical targets in the dataset are from different price levels, so the gap should be read as directional rather than precise.

ORTEX forecasts a 58% probability that Verastem joins the MSCI USA IMI, MSCI USA Small, MSCI World IMI, and MSCI World Small indices at the November 2026 quarterly review. The rank date was October 19, announcement is due November 11, and the trade date falls on November 30 with an effective date of December 1. The stock is already 7.5% above the entry line, having closed at $10 against a qualifying price of $9.25. If confirmed, index trackers would need to buy an estimated $43 million worth of stock, equal to roughly 1.3 days of average volume. That is a meaningful but not overwhelming forced buy. The important caveat is that this remains a forecast: the index provider has not confirmed it, and a drop back below the $9.25 price line before the review would change the calculation.

On earnings history, the pattern is unusually consistent. The last two distinct prints both produced next-day gains of approximately 15%, with five-day returns of 11% to 14% in each case. Q3 results are due November 5. Investors going into that print are therefore not operating in an information vacuum on how this stock tends to react.

The fortnight ahead features three potential catalysts in close succession: earnings on November 5, the MSCI announcement on November 11, and the index trade date on November 30. How shorts behave between earnings and the announcement, and whether availability tightens if index-related demand competes with the existing short base, are the variables worth tracking.